Alteogen
196170.KQAlteogen is a publicly-traded South Korean biotechnology company that develops biosimilars and innovative drug delivery solutions. The company leverages proprietary technology platforms to create improved formulations of existing biologics and develop novel therapeutic candidates. As a leader in the Asian biosimilar market, Alteogen has established partnerships with global pharmaceutical companies and continues to expand its pipeline across multiple therapeutic areas.
196170.KQ · Stock Price
Historical price data
AI Company Overview
Alteogen is a publicly-traded South Korean biotechnology company that develops biosimilars and innovative drug delivery solutions. The company leverages proprietary technology platforms to create improved formulations of existing biologics and develop novel therapeutic candidates. As a leader in the Asian biosimilar market, Alteogen has established partnerships with global pharmaceutical companies and continues to expand its pipeline across multiple therapeutic areas.
Technology Platform
Proprietary drug delivery and formulation technologies for enhanced bioavailability and stability of biological therapeutics, particularly focused on next-generation biosimilar development.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Healthy | Phase 1 | |
| ALT-BB4 + 0.9%NaCl | Health, Subjective | Phase 1 | |
| Eylea + ALT-L9 | Neovascular Age-related Macular Degeneration | Phase 1 | |
| ALT-P7 (HM2-MMAE) | HER2-positive Breast Cancer | Phase 1 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Operates in the highly competitive biosimilar market against both multinational pharmaceutical companies and specialized biosimilar developers. Differentiation through proprietary drug delivery technology platforms and strong position in the Asian market provide competitive advantages over pure-play biosimilar companies.